FDA Approves IMATINIB MESYLATE — Camber Pharmaceuticals, Inc.

# FDA Approves Generic Imatinib Mesylate Camber Pharmaceuticals, Inc. has received FDA approval for its generic formulation of imatinib mesylate, an oral tyrosine kinase inhibitor used to treat chronic myeloid leukemia and gastrointestinal stromal tumors. The approval is expected to increase competitive pricing pressure in the imatinib market and expand patient access to this critical oncology therapeutic.